abstract |
Diethyl- [6- (4-hydroxycarbamoyl-phenylcarbamoyloxymethyl) -naphthalen-2-yl methyl] -ammonium chloride, or other pharmaceutically acceptable salts and / or solvates, for use in the treatment of negative Philadelphia myeloproliferative syndromes, characterized in that The daily dose is from 10 to 150 mg per patient. |